Atherosclerotic Cardiovascular Disease Epidemiology, Pathophysiology, and Practical Risk Assessment

被引:0
|
作者
Derr, Jerica N. [1 ,2 ]
Black, Ashley [3 ,4 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Phys Assistant Educ, Div Educ, 2730 South Moody Ave, CL5PA, PORTLAND, OR 97201 USA
[2] Still Univ DMSc Program, Dept Phys Assistant Studies, Mesa, AZ USA
[3] Charleston Southern Univ, Coll Hlth Sci, Phys Assistant Studies Program, Hlth Sci Bldg,9200 Univ Blvd, Charleston, SC 29406 USA
[4] 117 Moon Shadow Lane, Summerville, SC 29485 USA
关键词
Atherosclerosis; ASCVD; Cardiovascular risk; Endothelial dysfunction; Plaque formation; Lifestyle modification; Risk assessment tools; HEART-DISEASE; MECHANISMS; GUIDELINE; ACC/AHA; THERAPY; US;
D O I
10.1016/j.cpha.2024.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In summary, ASCVD is a chronic condition driven by endothelial dysfunction and lipid accumulation, leading to plaque development and potential cardiovascular events. This article discusses key risk factors, including hypercholesterolemia, HTN, smoking, diabetes, and age, which collectively contribute to ASCVD progression. Understanding the pathophysiology of plaque formation-beginning with endothelial dysfunction and advancing to plaque rupture-is critical for clinical management. The use of risk assessment tools, such as the Framingham Risk Score and ACC/AHA Risk Estimator, provides clinicians with methods to evaluate and manage patient risk. This personalized approach can guide lifestyle and pharmacologic interventions that effectively mitigate ASCVD-related morbidity and mortality.
引用
收藏
页码:189 / 199
页数:11
相关论文
共 50 条
  • [21] Atherosclerotic cardiovascular disease risk among Ghanaians: A comparison of the risk assessment tools.
    Agyekum, Francis
    Akumiah, Florence Koryo
    Nguah, Samuel Blay
    Appiah, Lambert Tetteh
    Ganatra, Khushali
    Adu-Boakye, Yaw
    Folson, Aba Ankomaba
    Ayetey, Harold
    Owusu, Isaac Kofi
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 18
  • [22] Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors
    Meeusen, Jeffrey W.
    Donato, Leslie J.
    Kopecky, Stephen L.
    Vasile, Vlad C.
    Jaffe, Allan S.
    Laaksonen, Reijo
    CLINICA CHIMICA ACTA, 2020, 511 : 138 - 142
  • [23] Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options
    Marina Petrova Krasteva
    Kui Kai Lau
    Pasquale Mordasini
    Anderson Chun On Tsang
    Mirjam Rachel Heldner
    Advances in Therapy, 2020, 37 : 1829 - 1865
  • [24] Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options
    Krasteva, Marina Petrova
    Lau, Kui Kai
    Mordasini, Pasquale
    Tsang, Anderson Chun On
    Heldner, Mirjam Rachel
    ADVANCES IN THERAPY, 2020, 37 (05) : 1829 - 1865
  • [25] Risk-enhancing factors and social determinants of health in risk assessment for atherosclerotic cardiovascular disease
    Zhang, Yiyi
    An, Jaejin
    Xia, Mengying
    Zhou, Hui
    Sun, Yifei
    Chung, Joanie
    Zhou, Mengnan
    Choi, Soon Kyu
    Morrissette, Kerresa L.
    Muntner, Paul
    Safford, Monika M.
    Isasi, Carmen R.
    Kanaya, Alka M.
    Bellows, Brandon K.
    Colantonio, Lisandro D.
    Reynolds, Kristi
    Moran, Andrew E.
    PLOS ONE, 2024, 19 (10):
  • [26] Periodontal disease, a risk factor for atherosclerotic cardiovascular disease
    Gheorghita Dorottya
    Eordegh Gabriella
    Nagy Ferenc
    Antal Mark
    ORVOSI HETILAP, 2019, 160 (11) : 419 - 425
  • [27] Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
    Wei, Shibo
    Nguyen, Thanh T.
    Zhang, Yan
    Ryu, Dongryeol
    Gariani, Karim
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [28] Exploring bradykinin: A common mediator in the pathophysiology of sepsis and atherosclerotic cardiovascular disease
    Siti-Zubaidah, Mohd Zahari
    Harafinova, Harman-Shah
    Liba, Abdullahi Nuradeen
    Nordin, Muhammad Luqman
    Hambali, Kamarul Ariffin
    Siti, Hawa Nordin
    VASCULAR PHARMACOLOGY, 2024, 156
  • [29] ECONOMIC BURDEN OF DIABETIC PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marcellusi, A.
    Sciattella, P.
    Bini, C.
    Rotundo, M.
    Aimaretti, G.
    Mennini, F. S.
    VALUE IN HEALTH, 2020, 23 : S509 - S509
  • [30] Triglycerides and risk of atherosclerotic cardiovascular disease: An update
    Farnier, Michel
    Zeller, Marianne
    Masson, David
    Cottin, Yves
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2021, 114 (02) : 132 - 139